[
  {
    "ts": null,
    "headline": "Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say",
    "summary": "Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
    "url": "https://finnhub.io/api/news?id=b96ace001bc2759730c02331a3359d03369fd647268b12984c62b5de753a5628",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761863402,
      "headline": "Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say",
      "id": 137275123,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
      "url": "https://finnhub.io/api/news?id=b96ace001bc2759730c02331a3359d03369fd647268b12984c62b5de753a5628"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Dives As HIV Drug Misses Bullish Buy-Side Expectations",
    "summary": "Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention drug, Yeztugo.",
    "url": "https://finnhub.io/api/news?id=1fb6b13827e8938198f93ee0f69fed9151d9cb635ed718503dadabcf449f5441",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761860587,
      "headline": "Gilead Sciences Dives As HIV Drug Misses Bullish Buy-Side Expectations",
      "id": 137275124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention drug, Yeztugo.",
      "url": "https://finnhub.io/api/news?id=1fb6b13827e8938198f93ee0f69fed9151d9cb635ed718503dadabcf449f5441"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates",
    "summary": "Gilead (GILD) delivered earnings and revenue surprises of +14.88% and +4.16%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=d5ce10c348b157a0879ab49b9b672557dd01782c973adac206d014d6b5bb6da7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761858902,
      "headline": "Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates",
      "id": 137275125,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) delivered earnings and revenue surprises of +14.88% and +4.16%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=d5ce10c348b157a0879ab49b9b672557dd01782c973adac206d014d6b5bb6da7"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript",
    "summary": "Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDTCompany ParticipantsJacquie Ross - Senior Vice President of Treasury and...",
    "url": "https://finnhub.io/api/news?id=bfe543dc2ea3f91fd178250cd27110c58a0eefa28e2ed8a5b38953ea059ee8ba",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761857798,
      "headline": "Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript",
      "id": 137273002,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDTCompany ParticipantsJacquie Ross - Senior Vice President of Treasury and...",
      "url": "https://finnhub.io/api/news?id=bfe543dc2ea3f91fd178250cd27110c58a0eefa28e2ed8a5b38953ea059ee8ba"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Earnings Beat Expectations. The Stock Is Still Falling.",
    "summary": "Gilead  Sciences reported third-quarter results that surpassed Wall Street expectations late Thursday, amid a close focus on the launch of the company’s promising new HIV medicine.  Gilead shares are up 30% this year, largely on enthusiasm for Yeztugo, a twice-yearly HIV prevention shot that the FDA approved in June.  Gilead said Thursday that sales of Yeztugo had been $39 million in the third quarter.",
    "url": "https://finnhub.io/api/news?id=c3e1b69222ea593b36e75e45576111b75f94ed015fa39bacf2080ff8b71f0db9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761857100,
      "headline": "Gilead Earnings Beat Expectations. The Stock Is Still Falling.",
      "id": 137275126,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead  Sciences reported third-quarter results that surpassed Wall Street expectations late Thursday, amid a close focus on the launch of the company’s promising new HIV medicine.  Gilead shares are up 30% this year, largely on enthusiasm for Yeztugo, a twice-yearly HIV prevention shot that the FDA approved in June.  Gilead said Thursday that sales of Yeztugo had been $39 million in the third quarter.",
      "url": "https://finnhub.io/api/news?id=c3e1b69222ea593b36e75e45576111b75f94ed015fa39bacf2080ff8b71f0db9"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (NASDAQ:GILD) Exceeds Q3 Expectations",
    "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) announced better-than-expected revenue in Q3 CY2025, with sales up 3% year on year to $7.77 billion. On the other hand, the company’s full-year revenue guidance of $28.55 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $2.47 per share was 15.7% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=87f920cac074c9f3e520168401411334db4b440a37e10c207b3f7e689d489c20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761856100,
      "headline": "Gilead Sciences (NASDAQ:GILD) Exceeds Q3 Expectations",
      "id": 137275127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) announced better-than-expected revenue in Q3 CY2025, with sales up 3% year on year to $7.77 billion. On the other hand, the company’s full-year revenue guidance of $28.55 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $2.47 per share was 15.7% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=87f920cac074c9f3e520168401411334db4b440a37e10c207b3f7e689d489c20"
    }
  },
  {
    "ts": null,
    "headline": "Gilead: Q3 Earnings Snapshot",
    "summary": "GILD) on Thursday reported third-quarter earnings of $3.05 billion. On a per-share basis, the Foster City, California-based company said it had profit of $2.43. Earnings, adjusted for one-time gains and costs, came to $2.47 per share.",
    "url": "https://finnhub.io/api/news?id=9b3f860f1331c59b38640111055f0d0f4db4de3d8cc7220f6d2aac070a6dedfb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761855109,
      "headline": "Gilead: Q3 Earnings Snapshot",
      "id": 137275128,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "GILD) on Thursday reported third-quarter earnings of $3.05 billion. On a per-share basis, the Foster City, California-based company said it had profit of $2.43. Earnings, adjusted for one-time gains and costs, came to $2.47 per share.",
      "url": "https://finnhub.io/api/news?id=9b3f860f1331c59b38640111055f0d0f4db4de3d8cc7220f6d2aac070a6dedfb"
    }
  },
  {
    "ts": null,
    "headline": "Covid Continues To Haunt Gilead. How One Drug Dinged Product Sales.",
    "summary": "Big-name biotech Gilead Sciences issued a mixed third-quarter report late Thursday, with product sales coming in below expectations.",
    "url": "https://finnhub.io/api/news?id=7050d348e56000aecc8812250fde266467966350ac9b40f7e694bce055b9c4c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761854684,
      "headline": "Covid Continues To Haunt Gilead. How One Drug Dinged Product Sales.",
      "id": 137269247,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Big-name biotech Gilead Sciences issued a mixed third-quarter report late Thursday, with product sales coming in below expectations.",
      "url": "https://finnhub.io/api/news?id=7050d348e56000aecc8812250fde266467966350ac9b40f7e694bce055b9c4c3"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Announces Third Quarter 2025 Financial Results",
    "summary": "FOSTER CITY, Calif., October 30, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2025 results of operations.",
    "url": "https://finnhub.io/api/news?id=f5ba2ec73770098068f508cfb3253ffdbc61441bde7cd092f67d374a85d0a88f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761854520,
      "headline": "Gilead Sciences Announces Third Quarter 2025 Financial Results",
      "id": 137275129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., October 30, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2025 results of operations.",
      "url": "https://finnhub.io/api/news?id=f5ba2ec73770098068f508cfb3253ffdbc61441bde7cd092f67d374a85d0a88f"
    }
  },
  {
    "ts": null,
    "headline": "Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development",
    "summary": "New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board’s composition with the Company’s strategic direction and support its focus on transformational busin",
    "url": "https://finnhub.io/api/news?id=310d9372bd0403a76e90210f7ba09bd131a5b06924b0232bb8381ed4ed8604bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761854460,
      "headline": "Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development",
      "id": 137269248,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board’s composition with the Company’s strategic direction and support its focus on transformational busin",
      "url": "https://finnhub.io/api/news?id=310d9372bd0403a76e90210f7ba09bd131a5b06924b0232bb8381ed4ed8604bb"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. 2025 Q3 - Results - Earnings Call Presentation",
    "summary": "2025-10-30. The following slide deck was published by Gilead Sciences, Inc.",
    "url": "https://finnhub.io/api/news?id=8d9cff23cb6aba7a5e5cf0b60974c5c523324787cb9b8164a50a3aa6202b3dff",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761848830,
      "headline": "Gilead Sciences, Inc. 2025 Q3 - Results - Earnings Call Presentation",
      "id": 137272432,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "2025-10-30. The following slide deck was published by Gilead Sciences, Inc.",
      "url": "https://finnhub.io/api/news?id=8d9cff23cb6aba7a5e5cf0b60974c5c523324787cb9b8164a50a3aa6202b3dff"
    }
  }
]